Usefulness of rectally administering [1-13C]-butyrate for breath test in patients with active and quiescent ulcerative colitis

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 2, 2007, Pages 207-214

  Kato, Kimitoshi ^a   Ishii, Yukimoto ^a   Mizuno, Shigeaki ^a   Sugitani, Masahiko ^a   Asai, Satoshi ^a   Kohno, Tadashi ^b   Takahashi, Katsuyuki ^a   Komuro, Sachiko ^a   Iwamoto, Maho ^a   Miyamoto, Shunpachi ^a   Takayama, Tadatoshi ^a   Arakawa, Yasuyuki ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Frontier Technol Research Institute   (Japan)

Author keywords

13CO2 breath test; Active and quiescent ulcerative colitis; In vivo butyrate metabolism

Indexed keywords

BUTYRIC ACID 13 C; BUTYRIC ACID DERIVATIVE; CARBON DIOXIDE; ENEMA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREATH ANALYSIS; CARBON DIOXIDE EXCRETION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENDOSCOPY; EXPIRATORY FLOW RATE; FATTY ACID METABOLISM; FECES; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INFRARED SPECTROMETRY; MALE; MEASUREMENT; PRIORITY JOURNAL; REMISSION; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

ADMINISTRATION, RECTAL; ADULT; BREATH TESTS; BUTYRATES; CARBON DIOXIDE; CARBON ISOTOPES; COLITIS, ULCERATIVE; COLONOSCOPY; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 33846942224     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600955070     Document Type: Article

References (18)

1. Roediger WE. Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology 1982;83:424-9.
2. Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 1980;4:712-5.
3. Den Hond E, Hiele M, Evenepoel P, Peeters M, Ghoos Y, Rutgeerts P. In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. Gastroenterology 1998;115:584-90.
4. Simpson EJ, Chapman MA, Dawson J, Berry D, MacDonald IA, Cole A. In vivo measurement of colonic butyrate metabolism in patients with quiescent ulcerative colitis. Gut 2000;46:73-7.
5. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041.
6. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
7. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51-6.
8. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
9. Matts SGF. The value of rectal biopsy in the diagnosis of ulcerative colitis. Quart J Med 1961;120:393-407.
10. 2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man. Clin Chim Acta 1978;84:153-62.
11. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 1978;93:62-6.
12. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22:56-63.
13. Chapman MA, Grahn MF, Hutton M, Williams NS. Butyrate metabolism in the terminal ileal mucosa of patients with ulcerative colitis. Br J Surg 1995;82:36-8.
14. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833-7.
15. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43:29-32.
16. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
17. Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642-7.
18. Chapman MA, Grahn MF, Boyle MA, Hutton M, Rogers J, Williams NS. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut 1994;35:73-6.